Development and validation of a liquid chromatography-mass spectrometry assay for polymyxin B in bacterial growth media

Journal of Pharmaceutical and Biomedical Analysis

Volumn 92, Issue , 2014, Pages 177-182

  Cheah, Soon Ee ^a   Bulitta, Jurgen B ^a   Li, Jian ^a   Nation, Roger L ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Colistin; Liquid chromatography mass spectrometry; Mueller Hinton broth; Polymyxin B; Tryptone soya broth

Indexed keywords

COLISTIN; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; MUELLER-HINTON BROTH; POLYMYXIN B; TRYPTONE SOYA BROTH;

ANTI-BACTERIAL AGENTS; BIOLOGICAL ASSAY; CHROMATOGRAPHY, LIQUID; COLISTIN; CULTURE MEDIA; GRAM-NEGATIVE BACTERIA; MASS SPECTROMETRY; POLYMYXIN B;

EID: 84894087843     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2014.01.015     Document Type: Article

References (32)

1. Zavascki A.P., Goldani L.Z., Li J., Nation R.L. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J. Antimicrob. Chemother. 2007, 60:1206-1215.
2. Nation R.L., Li J. Colistin in the 21st century. Curr. Opin. Infect. Dis. 2009, 22:535-543.
3. Falagas M.E., Kasiakou S.K. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit. Care 2006, 10:R27.
4. Landman D., Georgescu C., Martin D.A., Quale J. Polymyxins revisited. Clin. Microbiol. Rev. 2008, 21:449-465.
5. Mouton J.W., Ambrose P.G., Canton R., Drusano G.L., Harbarth S., MacGowan A., Theuretzbacher U., Turnidge J. Conserving antibiotics for the future: new ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective. Drug Resist. Updates 2011, 14:107-117.
6. Tan C.H., Li J., Nation R.L. Activity of colistin against heteroresistant Acinetobacter baumannii and emergence of resistance in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob. Agents Chemother. 2007, 51:3413-3415.
7. Deris Z.Z., Yu H.H., Davis K., Soon R.L., Jacob J., Ku C.K., Poudyal A., Bergen P.J., Tsuji B.T., Bulitta J.B., Forrest A., Paterson D.L., Velkov T., Li J., Nation R.L. The combination of colistin and doripenem is synergistic against Klebsiella pneumoniae at multiple inocula and suppresses colistin resistance in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob. Agents Chemother. 2012, 56:5103-5112.
8. Bergen P.J., Li J., Nation R.L., Turnidge J.D., Coulthard K., Milne R.W. Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic model. J. Antimicrob. Chemother. 2008, 61:636-642.
9. Tam V.H., Schilling A.N., Neshat S., Poole K., Melnick D.A., Coyle E.A. Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 2005, 49:4920-4927.
10. Bulitta J.B., Landersdorfer C.B., Forrest A., Brown S.V., Neely M.N., Tsuji B.T., Louie A. Relevance of pharmacokinetic and pharmacodynamic modeling to clinical care of critically ill patients. Curr. Pharm. Biotechnol. 2011, 12:2044-2061.
11. Rybak M.J. Pharmacodynamics: relation to antimicrobial resistance. Am. J. Infect. Control 2006, 34:S38-S45. (discussion S64-S73).
12. Singh R., Tam V.H. Optimizing dosage to prevent emergence of resistance - lessons from in vitro models. Curr. Opin. Pharmacol. 2011, 11:453-456.
13. Orwa J.A., Govaerts C., Busson R., Roets E., Van Schepdael A., Hoogmartens J. Isolation and structural characterization of colistin components. J. Antibiot. (Tokyo) 2001, 54:595-599.
14. Orwa J.A., Govaerts C., Busson R., Roets E., Van Schepdael A., Hoogmartens J. Isolation and structural characterization of polymyxin B components. J. Chromatogr. A 2001, 912:369-373.
15. He J., Ledesma K.R., Lam W.Y., Figueroa D.A., Lim T.P., Chow D.S., Tam V.H. Variability of polymyxin B major components in commercial formulations. Int. J. Antimicrob. Agents 2010, 35:308-310.
16. Li J., Milne R.W., Nation R.L., Turnidge J.D., Coulthard K., Johnson D.W. A simple method for the assay of colistin in human plasma, using pre-column derivatization with 9-fluorenylmethyl chloroformate in solid-phase extraction cartridges and reversed-phase high-performance liquid chromatography. J. Chromatogr. B 2001, 761:167-175.
17. Cao G., Ali F.E., Chiu F., Zavascki A.P., Nation R.L., Li J. Development and validation of a reversed-phase high-performance liquid chromatography assay for polymyxin B in human plasma. J. Antimicrob. Chemother. 2008, 62:1009-1014.
18. Li J., Milne R.W., Nation R.L., Turnidge J.D., Coulthard K., Valentine J. Simple method for assaying colistin methanesulfonate in plasma and urine using high-performance liquid chromatography. Antimicrob. Agents Chemother. 2002, 46:3304-3307.
19. Cheng C., Liu S., Xiao D., Hollembaek J., Yao L., Lin J., Hansel S. LC-MS/MS method development and validation for the determination of polymyxins and vancomycin in rat plasma. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 2010, 878:2831-2838.
20. Jansson B., Karvanen M., Cars O., Plachouras D., Friberg L.E. Quantitative analysis of colistin A and colistin B in plasma and culture medium using a simple precipitation step followed by LC/MS/MS. J. Pharm. Biomed. Anal. 2009, 49:760-767.
21. Dotsikas Y., Markopoulou C.K., Koundourellis J.E., Loukas Y.L. Validation of a novel LC-MS/MS method for the quantitation of colistin A and B in human plasma. J. Sep. Sci. 2011, 34:37-45.
22. Kwa A.L., Lim T.P., Low J.G., Hou J., Kurup A., Prince R.A., Tam V.H. Pharmacokinetics of polymyxin B1 in patients with multidrug-resistant Gram-negative bacterial infections. Diagn. Microbiol. Infect. Dis. 2008, 60:163-167.
23. Gobin P., Lemaitre F., Marchand S., Couet W., Olivier J.C. Assay of colistin and colistin methanesulfonate in plasma and urine by liquid chromatography-tandem mass spectrometry. Antimicrob. Agents Chemother. 2010, 54:1941-1948.
24. Gikas E., Bazoti F.N., Katsimardou M., Anagnostopoulos D., Papanikolaou K., Inglezos I., Skoutelis A., Daikos G.L., Tsarbopoulos A. Determination of colistin A and colistin B in human plasma by UPLC-ESI high resolution tandem MS: application to a pharmacokinetic study. J. Pharm. Biomed. Anal. 2013, 83:228-236.
25. Soon R.L., Nation R.L., Cockram S., Moffatt J.H., Harper M., Adler B., Boyce J.D., Larson I., Li J. Different surface charge of colistin-susceptible and -resistant Acinetobacter baumannii cells measured with zeta potential as a function of growth phase and colistin treatment. J. Antimicrob. Chemother. 2011, 66:126-133.
26. Product information: CM0129, Tryptone soya broth, Oxoid, (accessed 19.08.13). http://www.oxoid.com/UK/blue/prod_detail/prod_detail.asp%3Fpr=CM0129.
27. Product information: CM0405, Mueller-Hinton broth, Oxoid, (accessed: 19.08.13). http://www.oxoid.com/UK/blue/prod_detail/prod_detail.asp%3Fpr=CM0405.
28. Nation R.L., Li J. Optimizing use of colistin and polymyxin B in the critically ill. Semin. Respir. Crit. Care Med. 2007, 28:604-614.
29. Zavascki A.P., Goldani L.Z., Cao G., Superti S.V., Lutz L., Barth A.L., Ramos F., Boniatti M.M., Nation R.L., Li J. Pharmacokinetics of intravenous polymyxin B in critically ill patients. Clin. Infect. Dis. 2008, 47:1298-1304.
30. Sandri A.M., Landersdorfer C.B., Jacob J., Boniatti M.M., Dalarosa M.G., Falci D.R., Behle T.F., Bordinhao R.C., Wang J., Forrest A., Nation R.L., Li J., Zavascki A.P. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. Clin. Infect. Dis. 2013, 57:524-531.
31. Boucher H.W., Talbot G.H., Bradley J.S., Edwards J.E., Gilbert D., Rice L.B., Scheld M., Spellberg B., Bartlett J. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 2009, 48:1-12.
32. Karvanen M.C., Mohamed A., Lagerbäck P., Friberg L.E., Cars O. Program and Abstract of the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (September 17-20) 2011, American Society for Microbiology, Chicago, IL.